BR112023002085A2 - Métodos para tratar hipercolesterolemia refratária envolvendo inibidor de angptl3 - Google Patents
Métodos para tratar hipercolesterolemia refratária envolvendo inibidor de angptl3Info
- Publication number
- BR112023002085A2 BR112023002085A2 BR112023002085A BR112023002085A BR112023002085A2 BR 112023002085 A2 BR112023002085 A2 BR 112023002085A2 BR 112023002085 A BR112023002085 A BR 112023002085A BR 112023002085 A BR112023002085 A BR 112023002085A BR 112023002085 A2 BR112023002085 A2 BR 112023002085A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- hypercholesterolemia
- involving
- angptl3
- statin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063062990P | 2020-08-07 | 2020-08-07 | |
| US202163135946P | 2021-01-11 | 2021-01-11 | |
| PCT/US2021/045008 WO2022032137A1 (en) | 2020-08-07 | 2021-08-06 | Methods for treating refractory hypercholesterolemia involving an angptl3 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023002085A2 true BR112023002085A2 (pt) | 2023-02-28 |
Family
ID=77543654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023002085A BR112023002085A2 (pt) | 2020-08-07 | 2021-08-06 | Métodos para tratar hipercolesterolemia refratária envolvendo inibidor de angptl3 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220072127A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4192446A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023538522A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230050379A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116096365A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021320417A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023002085A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3188213A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300429A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023001481A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022032137A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA43734A (fr) | 2016-03-03 | 2018-11-28 | Regeneron Pharma | Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3 |
| US12559551B2 (en) | 2019-05-24 | 2026-02-24 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ANGPTL3 antibodies |
| CA3246841A1 (en) * | 2022-04-04 | 2023-10-12 | Biomarin Pharmaceutical Inc. | TREATMENT FOR ENPP1 DEFICIENCY AND ABCC6 DEFICIENCY |
| WO2025185644A1 (zh) * | 2024-03-05 | 2025-09-12 | 江苏恒瑞医药股份有限公司 | 抗angptl3抗体治疗高血脂症的用途及方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| WO2012168491A1 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Pharmaceutical formulations of pcsk9 antagonists |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| AU2015289617B2 (en) * | 2014-07-16 | 2021-04-15 | Regeneron Pharmaceuticals, Inc. | Methods for treating high cardiovascular risk patients with hypercholesterolemia |
| KR20230074283A (ko) * | 2014-07-16 | 2023-05-26 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
| MA43734A (fr) * | 2016-03-03 | 2018-11-28 | Regeneron Pharma | Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3 |
| PL3439689T3 (pl) * | 2016-04-08 | 2022-01-31 | Regeneron Pharmaceuticals, Inc. | Sposoby leczenia hiperlipidemii inhibitorem angptl8 i inhibitorem angptl3 |
| MD3448426T2 (ro) * | 2016-04-28 | 2025-09-30 | Regeneron Pharma | Metode de tratament al pacienților cu hipercolesterolemie familială |
-
2021
- 2021-08-06 MX MX2023001481A patent/MX2023001481A/es unknown
- 2021-08-06 IL IL300429A patent/IL300429A/en unknown
- 2021-08-06 KR KR1020237007956A patent/KR20230050379A/ko active Pending
- 2021-08-06 WO PCT/US2021/045008 patent/WO2022032137A1/en not_active Ceased
- 2021-08-06 EP EP21762903.9A patent/EP4192446A1/en not_active Withdrawn
- 2021-08-06 BR BR112023002085A patent/BR112023002085A2/pt unknown
- 2021-08-06 US US17/396,399 patent/US20220072127A1/en not_active Abandoned
- 2021-08-06 CN CN202180058786.0A patent/CN116096365A/zh not_active Withdrawn
- 2021-08-06 CA CA3188213A patent/CA3188213A1/en active Pending
- 2021-08-06 JP JP2023507911A patent/JP2023538522A/ja not_active Abandoned
- 2021-08-06 AU AU2021320417A patent/AU2021320417A1/en not_active Abandoned
-
2023
- 2023-12-12 US US18/537,578 patent/US20240197870A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20220072127A1 (en) | 2022-03-10 |
| US20240197870A1 (en) | 2024-06-20 |
| JP2023538522A (ja) | 2023-09-08 |
| KR20230050379A (ko) | 2023-04-14 |
| CN116096365A (zh) | 2023-05-09 |
| EP4192446A1 (en) | 2023-06-14 |
| WO2022032137A1 (en) | 2022-02-10 |
| IL300429A (en) | 2023-04-01 |
| MX2023001481A (es) | 2023-03-08 |
| CA3188213A1 (en) | 2022-02-10 |
| AU2021320417A1 (en) | 2023-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017258105A1 (en) | Methods for treating patients with familial hypercholesterolemia | |
| MX2023001481A (es) | Metodos para tratar pacientes con hipercolesterolemia refractaria. | |
| EA201691847A1 (ru) | Способы снижения сердечно-сосудистого риска | |
| BR112022022578A2 (pt) | Novas composições e métodos de tratar doença covid-19 | |
| BR112022021322A2 (pt) | Anticorpo contra nectina-4 e aplicação do mesmo | |
| MX2018012221A (es) | Metodos para tratar hiperlipidemia con un inhibidor de proteina tipo angiopoyetina 8 y un inhibidor de proteina tipo angiopoyetina 3. | |
| BR112022024662A2 (pt) | Métodos para tratamento ou prevenção de infecções por sars-cov-2 e covid-19 com anticorpos de glicoproteína spike anti-sars-cov-2 | |
| BR112022004474A8 (pt) | Método de tratamento ou prevenção de um câncer em um sujeito, molécula de ligação ao antígeno para uso neste e uso desta | |
| BR112022026999A2 (pt) | Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas | |
| BR112018069732A2 (pt) | métodos para prevenir, tratar, reverter e/ou retardar angiogênese em um sujeito mamífero, para tratar um sujeito que sofre de uma doença ou condição angiogênica ocular e para inibir angiogênese do tumor | |
| BR112020016331A8 (pt) | Métodos para tratar câncer com anticorpos anti-pd-1 | |
| BR112022018157A2 (pt) | Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método para o tratamento e/ou prevenção do câncer | |
| DK1140170T3 (da) | Antistoffragmenter til topisk behandling af öjensygdomme | |
| BR112023020093A2 (pt) | Conjugado anticorpo-fármaco, incluindo anticorpo contra cldn18.2 humano, e uso do mesmo | |
| BRPI0211953B8 (pt) | anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro | |
| BR112021017303A2 (pt) | Conjugado de anticorpo ou um sal ou solvato farmaceuticamente aceitável deste, anticorpo que se liga com especificidade ao dlk1 ou um fragmento de ligação ao antígeno deste, composição farmacêutica para prevenção ou tratamento de doença proliferativa, câncer ou angiogênica, métodos para prevenção e para tratamento de doença proliferativa, câncer ou angiogênica, e, uso do conjugado | |
| MX2018002000A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
| BR112022016991A2 (pt) | Métodos para tratar um indivíduo humano que sofre de síndrome do desconforto respiratório agudo induzida por coronavírus ou pneumonia, para tratar, prevenir ou reduzir a gravidade ou coagulação ou trombose em um indivíduo humano infectado com vírus coronavírus da síndrome respiratória aguda grave 2 e para tratar, melhorar, prevenir ou reduzir o risco de desenvolver uma ou mais sequelas de longo prazo relacionadas ao coronavírus | |
| BR112019011350A2 (pt) | terapia de combinação | |
| BR112022010113A2 (pt) | Inibidores de vegf de longa ação para neovascularização intraocular | |
| BR112023022774A2 (pt) | Terapias de combinação para tratamento de câncer | |
| MX2023010764A (es) | Anticuerpo anti componente del complemento 1s (c1s). | |
| BR112022003884A2 (pt) | Tratamento de doença ou distúrbio hepático compreendendo antagonistas do receptor de actrii | |
| BR112022015800A2 (pt) | Tratamento de colangite biliar primária com elafibranor | |
| BR112023023453A2 (pt) | Anticorpo anti-tigit ou um fragmento de ligação ao antígeno deste e composições farmacêuticas compreendendo o referido anticorpo ou fragmento de ligação ao antígeno |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: ARQUIVADO O PEDIDO DE PATENTE, NOS TERMOS DO ARTIGO 86, DA LPI, E ARTIGO 14 DA PORTARIA 52/2023, REFERENTE AO NAO RECOLHIMENTO DA 5A RETRIBUICAO ANUAL.PARA FINS DE RESTAURACAO CONFORME ARTIGO 87, DA LPI 9.279, E ARTIGO 15, DA PORTARIA 52/2023, O DEPOSITANTE DEVERA, NO PRAZO DE 3 (TRES) MESES, PROCEDER COM:? PAGAMENTO DA GRU SERVICO 208, REFERENTE A TAXA DE RESTAURACAO DO PEDIDO.? PAGAMENTO DE 1 (UMA) GRU, SERVICO 221, REFERENTE(S) A(S) ANUIDADE(S) EM QUESTAO, NO VALOR EXTRAORDINARIO, CONFORME TABELA VIGENTE, SEGUNDO O ART. 84O 2O DA LEI NO 9.279/96. CASO NAO HAJA PAGAMENTO CONJUNTO, DENTRO DO PRAZO LEGAL, DAS RETRIBUICOES SUPRACITADAS, SERA MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, ATRA |